Online Supplementary Tables from Preclinical Therapeutic Synergy of MEK1/2 and CDK4/6 Inhibition in Neuroblastoma

Table S1. Specific mutations of genes listed in Table 1. Table S2. Foundation Medicine sequencing calls of cancer-specific gene panel. Table S3. Gene lists corresponding to microarray analysis described in Figures 1A and 1B: (A) binimetinib and (B) ribociclib. Significant genes (in bold type) are defined as having an adjusted p-value of 0.25 or less.表 S1：列于表 1 中的基因的特定突变。表 S2：Foundation Medicine 对癌症特异性基因组的测序结果。表 S3：对应于图 1A 和 1B 中描述的微阵列分析的基因列表：（A）binimetinib 及（B）ribociclib。显著基因（以粗体形式呈现）定义为调整后的 p 值不超过 0.25。